Performance snapshot and why Sabra might be on your radar

Sabra Health Care REIT (SBRA) has quietly put together a solid run, with the stock up about 2.5% over the past month and roughly 11% in the past 3 months.

For income focused investors watching healthcare real estate, that move, combined with a market value of about US$5.1b and reported annual revenue of US$815.664m, may prompt a closer look at what is driving sentiment.

At a share price of US$20.36, Sabra’s recent 2.5% 30 day share price return sits alongside a 6.3% year to date gain. Its 1 year total shareholder return of 25.7% and 3 year total shareholder return above 100% point to momentum that has been building over a longer period.

If Sabra’s mix of income and real estate exposure has caught your attention, it can be useful to see what else the market is rewarding in related areas such as healthcare focused technology. Consider scanning 33 healthcare AI stocks.

With Sabra trading at US$20.36 and sitting at an intrinsic value estimate that implies a sizeable discount, while also showing only a modest gap to analyst targets, the key question is simple: is there still value on the table, or is the market already paying up for future growth?

Most Popular Narrative: 7.5% Undervalued

Sabra’s fair value in the most widely followed narrative sits at $22.00 versus the last close at $20.36, setting up a modest valuation gap for investors to assess.

The limited new development of senior housing driven by elevated construction and financing costs has created a supply demand imbalance in key markets, giving Sabra pricing power for rent increases and occupancy gains, resulting in expanding margins and boosting net operating income.

Want to see what is behind that pricing power story? The narrative leans heavily on compounding revenue, steady margins and a premium earnings multiple. Curious which assumptions really carry that $22.00 fair value.

Result: Fair Value of $22 (UNDERVALUED)

However, the story can change quickly if new operators underperform, or if reimbursement and regulatory shifts pressure rent coverage and Sabra’s cash flow profile.

Next Steps

With both risks and rewards in play, do you feel the balance of this story fits your own view, or does the data point elsewhere? Take a closer look at the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Sabra has sharpened your focus on income and value, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Target resilient returns by checking companies that may offer robust income streams and capital strength through the 13 dividend fortresses.
• Hunt for potential mispriced opportunities that combine quality with attractive entry points using the 49 high quality undervalued stocks.
• Secure peace of mind by focusing on companies that show financial strength and resilience through the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.